GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus

Overview of attention for article published in Clinical Gastroenterology and Hepatology, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

news: 2 news outlets
twitter: 5 X users
patent: 1 patent

wikipedia: 1 Wikipedia page
guideline: 1 clinical guideline source

Readers on

mendeley: 46 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 15,679 followers.

RT @joaprimo: GLIMMER: A randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. @AGA…

RT @DrCynthiaLevy: Indeed a very important study. Itching can be challenging to manage - hopefully we will have better options soon! 🙏

RT @joaprimo: GLIMMER: A randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. @AGA…

GLIMMER: A randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. @AGA_CGH https://t.co/n8hn5u1x8p #PBC #LiverTwitter #OpenAccess https://t.co/BSHjHRymW3

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.